Navigation Links
IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Date:3/20/2008

any expects to receive a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008.

As previously announced, in the United States the Company continues to work with the Children's Oncology Group as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE and to respond to other questions in the non-approvable letter the Company received from the U.S. Food and Drug Administration (FDA). The Company expects to submit the amended new drug application (NDA) in the fourth quarter of 2008.

L-MTP-PE was granted orphan drug status in the United States in 2001 and in Europe in 2004. In Europe, the MAA was filed in November 2006 and in the U.S, the NDA was submitted to FDA in October 2006 and was accepted for review in December 2006.

As previously announced, the Company is evaluating the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

About Osteosarcoma

Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent s
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
9. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... CUPERTINO, Calif. , Aug. 27, 2015 ... management is scheduled to present at three upcoming healthcare ... , President and CEO, will present at the Rodman ... 10:00 a.m. Eastern time. The conference is being held ... York City . A live audio webcast of ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... THE WOODLANDS, Texas, Dec. 7, 2010 Community-based oncology practices ... iKnowMed PM. iKnowMed PM is offered by US Oncology, ... accessible via the Internet and customizable for community-based oncology practices. ... and can interface with a variety of other EHRs already ...
... Dec. 7, 2010 MedAvante, Inc., the leader in ... disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized ... Cipher recently announced the completion of the ... every patient is interviewed by a qualified MedAvante mental ...
Cached Medicine Technology:Community-Based Oncology Practices Have a New Affordable Practice Management System Offering by US Oncology 2Community-Based Oncology Practices Have a New Affordable Practice Management System Offering by US Oncology 3Community-Based Oncology Practices Have a New Affordable Practice Management System Offering by US Oncology 4Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study 2Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study 3
(Date:8/30/2015)... ... August 31, 2015 , ... The acknowledgement from Caribbean Journal comes after Grace ... 2015. The island of Providenciales itself received a TripAdvisor Traveller's Choice Award in ... Bay is offering a special promotion for newlyweds and honeymooners to celebrate this amazing ...
(Date:8/30/2015)... ... August 31, 2015 , ... ChopChop Kids, ... for Kids , recently elected two new officers to serve on the organization’s ... mission of inspiring and teaching kids to cook real food with their families ...
(Date:8/30/2015)... CA (PRWEB) , ... August 30, 2015 , ... ... announced a back to school special. The company is currently offering lice head checks ... In addition, the company is offering a 10% discount on their lice treatment products. ...
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert agrees to ... InHealth media is a global sales and communications firm that offers U.S. brands a ... our business relationship with Mr. Reid Eckert, as his interpretation of the nutritional needs ...
(Date:8/29/2015)... Tempe, AZ (PRWEB) , ... August 30, 2015 , ... ... of David O’Shea to serve as the college’s Vice President of Strategic Initiatives and ... years, is eager to help the college expand its reach and impact through innovative ...
Breaking Medicine News(10 mins):Health News:Grace Bay Beach Named a Top Beach Destination for Weddings 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2
... By Steven Reinberg HealthDay Reporter , MONDAY, Oct. ... appear to reduce the risk of having a baby with a ... or palette, a new study suggests. Neural tube birth ... are known to decrease when pregnant women take supplements of folic ...
... strength of its synapses -- the connections between neurons -- ... discovery that challenges conventional wisdom on the brain mechanisms of ... "rhythm," or frequency, for changing synaptic strength. And further, like ... a different optimal frequency for learning. The ...
... Mount Sinai School of Medicine have found that $6.7 billion ... unnecessary medications in primary care, with 86 percent of that ... high cholesterol. The findings are published in a research letter ... of Internal Medicine , one of the JAMA/Archives journals. ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... 10 parents don,t follow recommended vaccination guidelines for their ... involve skipping doses or delaying shots. And parents ... move toward an alternative schedule, according to new research. ...
... , MONDAY, Oct. 3 (HealthDay News) -- Among patients ... of sedation was not linked to an increased risk ... Swedish researchers report. "Neither duration of anesthesia nor ... with an increased risk for new malignant disease within ...
... whether or not to treat an ill resident on-site or send ... status. A new study out this month shows that on ... be sent to the hospital than individuals with private insurance ... health outcomes. "Nursing homes have an incentive to ...
Cached Medicine News:Health News:Mom's Healthy Diet Might Cut Birth Defect Risk 2Health News:Mom's Healthy Diet Might Cut Birth Defect Risk 3Health News:How the brain makes memories: Rhythmically! 2Health News:How the brain makes memories: Rhythmically! 3Health News:New research shows $6.7 billion spent on unnecessary tests and treatments in one year 2Health News:Some U.S. Parents Ignoring Vaccination Guidelines 2Health News:Some U.S. Parents Ignoring Vaccination Guidelines 3Health News:General Anesthesia Does Not Boost Cancer Risk, Study Finds 2Health News:Nursing home hospitalizations often driven by payer status 2Health News:Nursing home hospitalizations often driven by payer status 3Health News:Nursing home hospitalizations often driven by payer status 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: